At a glance
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) is a federal competitive grant from National Institutes of Health for the science & technology sector. Funding is up to $1,000M. Eligible applicants: Independent school districts; City or township governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); For profit organizations other than small businesses; Special distri. The application deadline is November 19, 2026. Apply via the official listing at www.grants.gov.
- Amount
- Up to $1,000M
- Deadline
- Nov 19, 2026
- Type
- Competitive
- Status
- Open
About this program
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.
Who can apply
Independent school districts; City or township governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); For profit organizations other than small businesses; Special district governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); State governments; Private institutions of higher education; Public housing authorities/Indian housing authorities; Small businesses; Native American tribal governments (Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; County governments. Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
How to apply
Apply through Grants.gov using funding opportunity number PAR-25-226. Register your organization (SAM.gov + Grants.gov) before the deadline, then submit the application package listed in the official notice.
Apply at official sourceRelated grants
- NSF Astronomy and Astrophysics Postdoctoral Fellowships NSF · Up to $110K · Oct 15, 2026 Open
- NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed) NIH · See listing · Jul 12, 2027 Open
- Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional) NIH · Up to $25K · Jun 2, 2027 Open
- Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required) NIH · See listing · Jun 7, 2028 Open